Candiplus® in the treatment of acute, recurrent and chronic vaginal mycoses.
Candiplus®, ProFem´s current lead product, is a new and proprietary medicine for the topical treatment of RVVC. Clinical safety was confirmed in a clinical pilot study in 2014. A phase 2 study performed in 2017 has shown superior efficacy compared to standard treatments. The combination medicine shows a completely new mode of action based on the synergistic effect of its components. By disrupting the biofilm and deactivating the pathogenic fungal hyphae, Candiplus® provides fast and effective treatment of the disease and prevents frequent recurrences and chronification. The rapid onset of pain relief is a very important additional benefit for patients.
Candiplus® (ProF-001) is superior to existing RVVC treatments.
Cellular adhesion plays a crucial role in the pathogenic switch of Candida yeasts, as well as in the formation of biofilms. By this, specific resistance mechanisms are induced, that lead to a clinical pattern of recurrent infections, which generally are very difficult to treat.
In Candiplus®, an antifungal active compound is combined with an anti-adhesive substance. The biofilm is broken up in a double attack targeting both adhesion within biofilms and interaction between host and pathogen.
Implementation of this concept in Candiplus® leads to a “first in class” medicine. Candiplus® is unique in its mode of action and does not have comparable competitors.
Worldwide, hundreds of millions of women suffer from acute vulvovaginal candidosis (VVC) at least once per year. The prevalence of this disease is reported to be between 25 and 40% of the female population aged 15 to 65.1
Around 6% (3-8%) of all women aged 15 to 65 are repeatedly or chronically suffer from vulvovaginal candidosis (recurrent vulvovaginal candidiasis: RVVC), representing approximately 150-200 m women.2
The recurrent/chronic form of the disease substantially reduces the quality of life for infected women, often for years, and currently cannot be cured effectively.3 Common therapy regimens have not improved for more than 30 years. In particular, the basic problem of RVVC being a biofilm-related infection has never been addressed successfully until now.